Multicentric Prospective Randomized Trial on Surgery Versus Standard Medical Care in Type 2 Diabetic Patients BMI 30-35

Not Applicable

• Conditions: Diabetes Mellitus
• Interventions: Procedure: Bariatric surgery

• Registration Number: NCT01041768
• Lead Sponsor: IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy

Brief Summary

200 type 2 diabetic patients -BMI between 30-35- will be submitted to bariatric surgery (biliopancreatic diversion BPD or gastric bypass GBP ) and 100 will receive standard medical treatment.

Subjects will be monitored during a 5 year period to assess the effects of the surgical procedures on diabetes resolution and control at 1, 3 and 5 years.

Detailed Description

The study is a multicentric prospective 2-arm randomized controlled trial. Only Centers with at least 50 bariatric surgeries performed during the time window January 2007 and September 2008 will be allowed to participate in the study.

Each Collaborating Center participating in the study will perform only one type of surgical procedure (GBP or BPD), depending on which one it is more familiar with.

Patients will be randomly assigned with a 2 to 1 ratio to receive either bariatric surgery (BS) (either GBP or BPD) or standard antidiabetic care (AC). The randomization will be centralized in the Coordinating Center. Patients assigned to BS will undergo GBP or BPD, depending on each Collaborating Center. Recruitment will continue, independently of the number of recruited patients per center, until the target of 200 GBP+BPD patients, and 100 AC patients will be attained.

After one year since enrollment, patients in AC group will be offered the choice to undergo one of the two surgical procedures, and then will follow the same protocol study as the other surgical patients. In addition, each Collaborating Center will be responsible for selecting one diabetic subject for each operated patient, matched as closely as possible with the patients assigned to surgical therapy, from the local population in medical treatment. These patients will serve as controls for long term mortality and morbidity.

Study Timeline

• Study Start: 2009-03
• Status Verified: 2009-12
• Study First Submitted: 2009-12-31
• Study First Submitted QC: 2009-12-31
• Study First Posted: 2010-01-01
• Last Update Submitted: 2010-03-29
• Last Update Posted: 2010-03-30
• Primary Completion: 2010-12
• Study Completion: 2015-12

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 300

Inclusion Criteria

• BMI ≥30 and ≤34.9 kg/m2
• age between 35 and 70 years
• duration of diabetes ≥ 5 years
• poor glycemic control (i.e., HbA1c ≥ 8%) in spite a medical antidiabetic therapy in accordance with good clinical practice (GCP)
• presence of significant co-morbidities or complications (such as dyslipidemia, arterial hypertension, impaired renal function, neuropathy, retinopathy, CVD)

Exclusion Criteria

• specific contraindication to obesity surgery or GBP or BPD, including any gastric alteration specifically contraindicating GBP
• HbA1c < 8%
• positive autoantibodies anti-pancreas islet
• serum C-peptide < 0.5 ng/ml
• pregnancy
• medical conditions requiring acute hospitalisation
• severe diabetes complications or associated medical conditions (such as blindness, end-stage renal failure, liver cirrhosis, malignancy, chronic congestive heart failure
• recent (within preceding 12 months) myocardial infarction, stroke or TIA
• unstable angina pectoris
• psychological conditions which may hamper patient's cooperation
• geographic inaccessibility
• any condition which, in the judgement of the Investigator, may make risky the participation in the study or bias the results

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
antidiabetic medical therapy	Bariatric surgery	-
Bariatric Surgery	Bariatric surgery	-

Primary Outcome Measures

Name	Time	Method
Proportion of patients achieving diabetes complete remission (HbA1c 6% or below) or diabetes control (HbA1c between 7% and 6.1%) on free diet and with no antidiabetic medical therapy.	year 1, 3, 5

Secondary Outcome Measures

Name	Time	Method
Stable reduction of preoperative HbA1c; BMI; mortality/morbidity; Major components of the metabolic syndrome; Diabetes complications; Improvement of beta-cell function; insulin resistance reduction ; Overall and CV disease mortality.	at and post surgery, 1,3, 5 years since randomization

Trial Locations

Locations (1)

Azienda Ospedaliera Universitaria "San Martino"; 🇮🇹 Genova, Italy